5101
CD19
Non-Hodgkin’s lymphoma (NHL)
Our Pipeline
We are pioneering for patients and are working tirelessly to bring value to all our stakeholders.
Our pipeline represents a commitment to transforming the way patients are treated, with programs in discovery through to late-stage clinical development.
Oncology
CAR-T
Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
5201
CD19
Chronic lymphocytic leukemia (CLL)
Including Richter Transformation (RT)
Including Richter Transformation (RT)
5301
BCMA
Multiple myeloma (MM)
Multiple targets
Immunology
Small molecules
Program
Target
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
3667
TYK2
Systemic lupus erythematosus (SLE)
3667
TYK2
Dermatomyositis (DM)
Multiple targets
Visit our Clinical Trials Portal
Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.
Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.
Our stories
More about our company, science and people
We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos
Partnerships
Work with us!
We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!
Investor Hub
All information for investors…
… centralized in one Investor Hub. Discover how we aim to create value for all our stakeholders.